Clene (NASDAQ:CLNN) Given Buy Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Clene (NASDAQ:CLNN) in a research report sent to investors on Friday morning,Benzinga reports. They currently have a $23.00 price objective on the stock.

Other analysts have also recently issued research reports about the stock. Benchmark reiterated a “buy” rating on shares of Clene in a research note on Thursday, December 4th. UBS Group reiterated a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Clene in a report on Tuesday, October 14th. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Clene presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Clene Stock Up 7.0%

NASDAQ:CLNN opened at $6.39 on Friday. The company has a market capitalization of $66.01 million, a PE ratio of -1.88 and a beta of 0.87. Clene has a 52-week low of $2.28 and a 52-week high of $13.50. The stock’s 50 day moving average price is $7.68 and its 200 day moving average price is $6.41.

Clene (NASDAQ:CLNN) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The business had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.06 million. As a group, sell-side analysts anticipate that Clene will post -5.19 EPS for the current fiscal year.

Insider Buying and Selling at Clene

In other news, major shareholder Chidozie Ugwumba sold 5,869 shares of Clene stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $5.87, for a total value of $34,451.03. Following the sale, the insider owned 760,611 shares of the company’s stock, valued at $4,464,786.57. The trade was a 0.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 321,677 shares of company stock valued at $2,113,866 over the last quarter. 35.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Clene

A number of hedge funds have recently added to or reduced their stakes in the company. Lunt Capital Management Inc. boosted its holdings in Clene by 71.2% in the 2nd quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of Clene in the 2nd quarter valued at approximately $47,000. Scoggin Management LP boosted its stake in shares of Clene by 42.8% in the second quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after buying an additional 42,750 shares in the last quarter. Finally, Jones Financial Companies Lllp acquired a new position in Clene during the third quarter worth $29,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).